Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?


Rexahn Pharmaceuticals (RNN) Continues to Spike on Potential Cancer Pill, Roth Upgrade

By  +Follow January 13, 2014 10:17AM
Tickers Mentioned:

Shares in Rexahn Pharmaceuticals (RNN) jumped nearly 40 percent on Monday, continuing a bull-run that has the stock up over 150 percent since Thursday and over 265 percent in the last month on a promising potential cancer treatment and the initiation of relatively bullish coverage from Roth Capital Markets analysts.

RNN’s RX-3117 Could be Alternative for Eli Lilly’s Gemzar

Driving the current growth-spurt is the announcement of the initation of Phase 1b to study the safety and efficacy of RX-3117, Rexahn’s lead drug candidate, in cancer patients with solid tumors. The hype surrounding RX-3117 is considerable given that it has to potential to function as an oral to Eli Lilly’s (LLY) Gemzar.

"The initiation of this Phase I clinical trial of RX-3117 represents an important milestone for Rexahn," said CEO Peter D. Suzdak, Ph.D. "This compound is exciting to work with, as it has a unique profile with demonstrated activity against gemcitabine-resistant human cancer cells. We were pleased to see reduced side effect liability and oral bioavailability in cancer patients in our initial exploratory Phase I clinical trial conducted in Europe, and we believe that RX-3117 may represent a significant advancement in the treatment of cancer patients with solid tumors."

Gemzar is an injectable drug that results in resistance for 1 out of 4 patients, making an alternative that functions in pill form one with considerable commercial potential.

Analyst Seems Convinced

Also helping boost shares over the past few days was the news from Thursday that Roth Capital Markets’ Joe Pantiginis had initiated coverage on the stock at a “buy” rating with a price target of $3, still nearly double the current share price even after the spike in price.

Along with the considerable potential for RX-3117, the company boasts nearly $15 million in cash as well as over $5 million in new funding, giving it enough money to carry it for two years.


DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions.

Liked What You Read? Join Equities.com as a contributor and get eyeballs on your content FOR FREE!

Results for rnn
24 Oct 14 19:05:51
RNN 0.7567 Stock Charts $RNN Rexahn Pharmaceuticals Inc. (NYSE MKT) Last Updated: 10/24/2014 21:05:50 RNN Stoc http://t.co/380kn4j2S0
24 Oct 14 14:52:32
http://t.co/rCFETx8Oyc hogfan2: $RNN added today...hog: hogfan2 http://t.co/OfqYwdUvGk http://t.co/rCFETx8Oyc
Rick Dumont
23 Oct 14 20:59:56
$RNN...I am looking at it...I think in 6 months it's higher.
Investors Hangout
23 Oct 14 19:56:08
chartguy89: RNN 0.758 Stock Charts $RNN Rexahn http://t.co/Qh4TnAuVFw
Investors Hangout
23 Oct 14 19:56:07
chartguy89: RNN 0.758 Stock Charts $RNN Rexahn http://t.co/gYNd8cEjBD
23 Oct 14 19:37:35
http://t.co/jYcEVtZYAh Stock_Tracker: Stock DD Board: Rexahn Pharmaceuticals (RNN) 0.76 $RNN Metastatic http://t.co/KDKBAJIJyA
23 Oct 14 19:37:32
http://t.co/jYcEVtZYAh chartguy89: Stock Charts: RNN 0.758 Stock Charts $RNN Rexahn http://t.co/1nuhnYmqlf
23 Oct 14 19:30:29
RNN 0.758 Stock Charts $RNN Rexahn Pharmaceuticals Inc. (NYSE MKT) Last Updated: 10/23/2014 21:30:28 RNN Stock http://t.co/qJsj6PkRMs
Ish Capital ™
23 Oct 14 15:23:48
What a nice day $JNUG $PLUG $RNN
Michele Ciani
23 Oct 14 10:06:32
Strong day for my small cap bio stocks. $CYTR $ADXS $CPRX $ALXA $CLDX $SPPI $CYCC $RNN acting great. Holding all long
23 Oct 14 05:29:08
RT @micheleciani: #biotech #buy #stocks $RNN $RPRX $OCRX $CYCC $KBIO $ECYT $IPCI $SPHS $LPDX $VSTM $AEZS $AGEN and others http://t.co/MyO7l…
Michele Ciani
23 Oct 14 04:59:00
#biotech #buy #stocks $RNN $RPRX $OCRX $CYCC $KBIO $ECYT $IPCI $SPHS $LPDX $VSTM $AEZS $AGEN and others http://t.co/MyO7lZcSqh
Jet Life PennyStock$
23 Oct 14 01:39:06
Dollar$OnPennies: $RNN Gallery View http://t.co/CsNySBpbzH
23 Oct 14 01:33:27
Dollar$OnPennies: $RNN Gallery View http://t.co/Mkq32ShtOU
22 Oct 14 11:45:37
http://t.co/rCFETx8Oyc SwingKing: Anyone still in $RNN?: SwingKing http://t.co/Vu0xzfhIx6 http://t.co/rCFETx8Oyc
22 Oct 14 11:35:05
$RNN on watch, volume
22 Oct 14 11:28:45
$RNN looking good.. Nice support around .69 - .71 Long and strong!
Andrés De Sousa E.
22 Oct 14 07:54:47
$RNN half daily vol and up 5% ...someone is buying hard
Stock Status
22 Oct 14 07:10:22
GREEN! $TTNP http://t.co/juihUiv41A $RNN http://t.co/iE34KlXG3e $PRAN http://t.co/er9pRC83sT $IMUC http://t.co/4en6IJq2wn
22 Oct 14 06:49:22
$RNN nice to see in green dress
22 Oct 14 02:03:53
Dollar$OnPennies: $RNN Gallery View http://t.co/ZXc21pbVeq
22 Oct 14 02:03:37
Dollar$OnPennies: $RNN Gallery View http://t.co/m4LpvhN2o8
21 Oct 14 12:07:13
$RNN dead stock
WallStreet Pennies
21 Oct 14 01:38:37
Dollar$OnPennies: $RNN Gallery View http://t.co/UggjcobHyn
21 Oct 14 01:34:40
Dollar$OnPennies: $RNN Gallery View http://t.co/rjEERFcDgw
Stephen P Kendal
20 Oct 14 08:15:15
$RNN #UnderValued #MktCap=$124.78M. #52WkH/L=$1.85/$0.37. #LowTarget=$1.00 +43%. #MeanTarget=$2.20 +214%. Price=$0.70. #BuyRec #12. LT=⇗
20 Oct 14 06:27:56
20 Oct 14 02:33:33
Dollar$OnPennies: $RNN Gallery View http://t.co/bdYvBtmV9v
19 Oct 14 18:56:41
@sgerat RX-3117 data expected in 2014Q4/2015Q1. $RNN
19 Oct 14 18:55:11
$RNN Rexahn milestone events for remaining year 2014. #HighVolatility #HighRiskReward #ClinicalData http://t.co/HPiKRPMatQ
Stocks News&Markets
18 Oct 14 10:01:40
lx21 made $55,733 on $RNN -Check it out! http://t.co/WqX5rSCDIW Learn #howtotrade http://t.co/axK8SMSgo9 $COCO $HDSN $BIOF $DLIA $LIME
Day Traders Group
17 Oct 14 16:43:17
Stochastic Bullish Crossovers http://t.co/pqsiM7anI8 $TFX $VTR $STZ $STJ $SYK $RNN $WYY $AAPL $PCLN $QQQ $FB $TWTR $WFC $MU $DD & More
By  +Follow January 13, 2014 10:17AM



blog comments powered by Disqus

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.